Transpire Bio, a start-up inhaled drug developer based in Florida, has announced the appointment of two more OINDP experts, naming William Schachtner as Chief Technical Operations Officer and Axel Perlwitz as Chief Regulatory Affairs Officer. Like Transpire CEO Xian-Ming Zeng and Chief Medical Officer Mark Lepore, both Schachtner and Perlwitz previously held positions at Lupin’s Inhalation Research Center in Florida.
At Lupin, Schachtner first served as Director of Program Management for pMDI and later in roles as Director of Inhalation Technical Support and Senior Director of Project and Manufacturing Management. His prior positions include inhalation development roles at PPD and 3M Drug Delivery. Perlwitz most recently served as Sr. Director Regulatory Affairs Inhalation R&D and previously held roles in regulator affairs for respiratory drugs at Glenmark and Teva after having worked in inhalation science positions at Primedica and Cardinal health / Catalent Pharma Solutions.
In July 2022, Transpire Bio announced that it had contracted with Recipharm for development of two generic MDI formulations for the treatment of asthma and COPD. In September 2022, the company announced a second agreement with Recipharm for development of two additional inhaled drug candidates.
Zeng commented, “I am most delighted to welcome Axel and Bill to the Transpire Bio team. Their extensive experiences in inhalation CMC and Regulatory Affairs will play an instrumental role in advancing both our generic and innovative product pipelines. I very much look forward to working with both as we continue to build our R&D capabilities, advance and expand our product pipelines into 2023 and beyond.”
Schachtner said, “I am excited to join Transpire Bio and share their vision of improving patient access to important inhalation products. I am humbled to be a part of such a talented team of inhalation development experts and look forward to expanding the capabilities of inhalation therapy by creating novel treatments for serious lung and systemic diseases.”
Perlwitz added, “Transpire Bio has an exciting pipeline, and I am thrilled at the opportunity to continue developing new products right here in South Florida, those that drive patient access to both innovative inhalation therapies for unmet medical needs, as well as continued access to affordable generic medicines for respiratory diseases. Joining new team members and former colleagues with whom I have had the pleasure to collaborate in the inhalation space for close on 20 years is an excellent basis for a strong team.”
Read the Transpire Bio press release.
